8-K: 2seventy bio Reports Strong Abecma Sales Growth and Cost Savings in Q3 2024

2seventy bio announced a 42% increase in Abecma sales compared to the previous quarter, alongside significant cost reductions and a net loss of approximately $10 million for the third quarter of 2024.

Summary

• 2seventy bio reported a 42% increase in Abecma U.S. commercial revenue, reaching $77 million in the third quarter of 2024 compared to the second quarter.
• The company expects Abecma revenues to be between $240 and $250 million for the full year of 2024.
• A decision to discontinue enrollment in the KarMMa-9 study is expected to result in over $80 million in cost savings over the next several years.
• Operating expenses were reduced by 24% compared to the second quarter, reflecting progress in streamlining the cost structure.
• The net loss for the third quarter was approximately $10 million, a significant improvement from the $71.6 million loss in the same quarter of the previous year.
• 2seventy bio ended the quarter with approximately $192 million in cash, cash equivalents, and marketable securities, with an expected cash runway beyond 2027.
• Total revenues for the quarter were $13.5 million, compared to $12.0 million in the same quarter of 2023.
• Research and development expenses decreased to $8.3 million for the quarter, compared to $51.3 million in the same quarter of 2023.
• Selling, general, and administrative expenses were $12.9 million for the quarter, compared to $13.0 million in the same quarter of 2023.
• The company reiterates its net cash spend range of $40-60 million for 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong sales growth, significant cost reductions, and a clear path to profitability. The strategic decision to discontinue the KarMMa-9 study is a prudent move to conserve resources. The company's cash runway is also a positive sign. However, the reliance on a single product and the competitive landscape are potential risks.

Positives

• Abecma sales are showing strong growth, indicating increasing market adoption.
• Significant cost reductions have been achieved through streamlining operations and strategic realignment.
• The company's cash position is strong, providing a long runway for future operations.
• The net loss has significantly decreased, showing progress towards profitability.
• The company is focused on the commercialization of Abecma, which is a positive strategic move.
• Real-world evidence supports Abecma's safety and efficacy profile.
• The company has successfully executed the sale of R&D assets to Regeneron and Novo Nordisk.

Negatives

• Total revenues for the nine months ended September 30, 2024, were $34.9 million, compared to $89.7 million for the same period in 2023, indicating a significant decrease.
• The company is still operating at a loss, although the loss has been reduced.
• The discontinuation of the KarMMa-9 study may impact future development plans.
• The company is reliant on Bristol Myers Squibb for the commercialization of Abecma.

Risks

• The company's reliance on the commercial success of Abecma poses a risk if sales do not meet expectations.
• The competitive landscape for multiple myeloma treatments is intense, which could impact Abecma's market share.
• There are risks associated with the manufacturing and supply of Abecma.
• The company's ability to manage operating expenses and cash use is critical for achieving profitability.
• The company is subject to risks related to clinical trials and regulatory approvals.
• The company is subject to risks related to the safety and efficacy of Abecma, including potential adverse events.

Future Outlook

The company expects continued growth in Abecma sales and aims to achieve breakeven operations. They anticipate a cash runway beyond 2027 and are focused on expanding the reach of Abecma to more patients.

Management Comments

• Chip Baird, chief executive officer, stated that 2seventy continues to make meaningful progress on our goal of achieving breakeven operations.
• Chip Baird also noted that Abecma has a differentiated safety profile and that physicians understand that with effective use of bridging, they can achieve deep and durable responses.

Industry Context

The announcement reflects the growing importance of CAR-T therapies in the treatment of multiple myeloma. The competitive landscape is intense, with several companies developing similar treatments. 2seventy bio's focus on Abecma and cost management is a strategic response to this environment.

Comparison to Industry Standards

• The 42% quarter-over-quarter growth in Abecma sales is a positive sign, indicating strong market adoption compared to other CAR-T therapies in the same space.
• The reduction in operating expenses by 24% is significant and suggests that 2seventy bio is effectively managing its costs, which is crucial for biotech companies in the development stage.
• The company's cash runway extending beyond 2027 is a positive indicator of financial stability, which is better than many other biotech companies that often face near-term funding challenges.
• The net loss of approximately $10 million for the quarter is a substantial improvement compared to the $71.6 million loss in the same quarter of the previous year, showing progress towards profitability, which is a key metric for investors.
• The discontinuation of the KarMMa-9 study to save over $80 million is a strategic move to optimize resource allocation, which is a common practice in the biotech industry to focus on the most promising programs.

Related Party Transactions

• 2seventy bio and BMS share equally in all profits and losses related to development, manufacturing, and commercialization of Abecma in the U.S.

Stakeholder Impact

• Shareholders will benefit from the increased revenue, reduced losses, and extended cash runway.
• Employees may experience job security due to the company's improved financial position.
• Patients will benefit from the continued availability of Abecma and potential expansion of its use.
• Suppliers and creditors will have increased confidence in the company's ability to meet its obligations.

Next Steps

• Continue to focus on the commercialization of Abecma.
• Further optimize the real-world use of Abecma.
• Continue to invest in additional studies to generate data.
• Monitor the competitive landscape and adapt strategies as needed.

Key Dates

Keywords

Abecma, Multiple Myeloma, CAR-T Therapy, Financial Results, Cost Savings, Commercialization, 2seventy bio, KarMMa-3, BMS, Revenue, Net Loss, Operating Expenses